For hypertrophic obstructive cardiomyopathy, what is the first-line pharmacologic therapy?

For hypertrophic obstructive cardiomyopathy, what is the first-line pharmacologic therapy?

• A. Nitrates
• B. ACE inhibitors
• C. Digoxin
• D. Beta-blockers

Answer: (D)

In hypertrophic obstructive cardiomyopathy, the dynamic obstruction of the left ventricular outflow tract is driven by high obstruction with tachycardia and strong contractility. The best first-line pharmacologic approach is a beta-blocker because it slows the heart rate and reduces contractility, which shortens the systolic ejection phase and decreases the force driving the mitral valve toward the septum. This combination lowers the LVOT gradient, improves diastolic filling, and relieves symptoms like dyspnea and chest pain. Nitrates and diuretics can reduce preload, often worsening the obstruction. ACE inhibitors reduce afterload but can cause hypotension and may not improve the gradient in obstructive physiology. Digoxin increases contractility, which can worsen the dynamic obstruction. If beta-blockers aren’t tolerated or adequate, alternatives like certain calcium channel blockers or other therapies may be considered, but they aren’t the preferred first choice.

In hypertrophic obstructive cardiomyopathy, the dynamic obstruction of the left ventricular outflow tract is driven by high obstruction with tachycardia and strong contractility. The best first-line pharmacologic approach is a beta-blocker because it slows the heart rate and reduces contractility, which shortens the systolic ejection phase and decreases the force driving the mitral valve toward the septum. This combination lowers the LVOT gradient, improves diastolic filling, and relieves symptoms like dyspnea and chest pain.

Nitrates and diuretics can reduce preload, often worsening the obstruction. ACE inhibitors reduce afterload but can cause hypotension and may not improve the gradient in obstructive physiology. Digoxin increases contractility, which can worsen the dynamic obstruction. If beta-blockers aren’t tolerated or adequate, alternatives like certain calcium channel blockers or other therapies may be considered, but they aren’t the preferred first choice.